Related Experiment Videos
Circulating tumor cells in urological cancers.
Martin Cegan, Christopher Kobierzycki, Katarina Kolostova
1Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic; Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland; 3rd Department of Surgery, Motol University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic. vbobek@centrum.cz.
Folia Histochemica Et Cytobiologica
|October 11, 2017
Summary
Circulating tumor cells (CTCs) are key indicators in metastatic cancer. Analyzing CTCs in urological cancers aids in personalized treatment and improved diagnostics.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Circulating tumor cells (CTCs) are rare cancer cells in the bloodstream during metastatic disease.
- CTCs serve as a negative prognostic marker, indicating disease progression.
- Their presence and characteristics vary across different cancer types.
Purpose of the Study:
- To analyze recent data on CTCs in urological cancers.
- To explore the potential diagnostic and therapeutic applications of CTCs.
- To highlight the value of CTC analysis for molecular profiling and personalized medicine.
Main Methods:
- Review and analysis of recent scientific literature on CTCs in urological cancers.
- Focus on methodologies for determining CTC percentages and population size.
- Exploration of biological characteristics of CTCs in advanced cancer stages.
Main Results:
- CTC percentages differ significantly among various urological cancer types.
- CTCs hold potential for both diagnostic and therapeutic applications.
- Quantifying and analyzing CTCs can facilitate molecular profiling.
Conclusions:
- CTC analysis is crucial for advancing diagnostics in urological cancers.
- Understanding CTC biology supports the development of personalized treatment strategies.
- Further research into CTCs promises significant clinical utility in oncology.